Analysis of Long-term Survivors After Surgical Resection for Pancreatic Cancer

Han, Sang Jun; Jang, Jin-Young; Kim, Sun‐Whe; Kim, Woo Ho; Lee, Kuhn Uk; Park, Yong-Hyun

doi:10.1097/01.mpa.0000202953.87740.93

Cited by 150 publications

(106 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The authors found that the prognosis of the patients with large tumors was significantly worse than that of the subjects with small tumors. Similar results have been observed in previous reports 16,17) . Furthermore, analyses of 396 and 185 patients with pancreatic cancer showed that a tumor size of ≤ 2 cm is a significant prognostic factor 18,19) .…”

Section: Discussionsupporting

confidence: 82%

Pathological tumor size is an independent prognostic factor in pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy with S-1

Aoyama

Murakawa

Yamaoku

et al. 2017

Ann. Cancer Res. Therap.

View full text Add to dashboard Cite

Background: The objective of this retrospective study was to clarify prognostic factors in pancreatic cancer patients treated with curative resection followed by adjuvant chemotherapy with S-1. Methods: Both overall survival (OS) and recurrence-free survival (RFS) were examined in 76 pancreatic cancer patients who underwent curative surgery and received adjuvant chemotherapy with S-1 after surgery between 2007 and 2014. Results: When the length of OS was evaluated according to the log-rank test, significant differences were observed in the pathological tumor size. In addition, univariate and multivariate Cox's proportional hazards analyses demonstrated that the pathological tumor size was the only significant independent prognostic factor for both OS and RFS. The 5-year OS was 0% in the pathological tumor size ≥ 60 mm group and 30.4% in the pathological tumor size < 60 mm group (p= 0.010). Moreover, similar results were observed for recurrence-free survival (p= 0.008). Conclusions:The pathological tumor size is the most important prognostic factor for OS and RFS in patients with pancreatic cancer treated with curative resection followed by adjuvant chemotherapy with S-1. The present results suggest that adjuvant chemotherapy with S-1 is not sufficient, especially in patients with relevant risk factors.

show abstract

Section: Discussionsupporting

confidence: 82%

Pathological tumor size is an independent prognostic factor in pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy with S-1

Aoyama

Murakawa

Yamaoku

et al. 2017

Ann. Cancer Res. Therap.

View full text Add to dashboard Cite

show abstract

“…[4][5][6][7][8][9][10][11][12][13] Clinicopathological features associated with improved survival at 5 years post-resection include small tumor size (< 2 cm), negative lymph node status, negative resection margin (i.e., R0), absence of angiolymphatic and perineural invasion, and low grade of differentiation. Relatively longer (i.e., ≥ 5 y) survival after surgery for PDAC has been increasing for the last two decades, largely due to centralization of surgery to high-volume (i.e., expert) centers.…”

Section: Introductionmentioning

confidence: 99%

Stromal galectin-1 expression is associated with long-term survival in resectable pancreatic ductal adenocarcinoma

Chen

Pan

Ottenhof

et al. 2012

Cancer Biology & Therapy

View full text Add to dashboard Cite

“…Survival after resection remains disappointing, with 5-year survival rates ranging from 10% to 29% [3][4][5][6][7][8] . Advances in diagnostic and operative techniques and in perioperative care have increased the resectability of pancreatic cancer, and have decreased rates of operative morbidity and mortality.…”

Section: Introductionmentioning

confidence: 99%

“…Advances in diagnostic and operative techniques and in perioperative care have increased the resectability of pancreatic cancer, and have decreased rates of operative morbidity and mortality. The definition of a resectable tumor has become more clearly defined anatomically based on the availability of high-quality computed tomography (CT) scans [7][8][9][10] . Such imaging now permits a precise, preoperative, noninvasive assessment of tumor respectability and adds an important level of objectivity to the staging of patients for entry into clinical trials.…”

Section: Introductionmentioning

confidence: 99%

Radical resection and outcome for malignant tumors of thepancreatic body and tail

Han¹,

Zhang²,

Zheng³

et al. 2009

WJG

View full text Add to dashboard Cite

AIM:To analyze the factors influencing radical (R0) resection rate and surgical outcome for malignant tumor of the pancreatic body and tail. METHODS:The clinical and operative data and followup results of 214 pancreatic body and tail cancer patients were analyzed retrospectively. RESULTS:One hundred and twenty/214 pancreatic body and tail cancer patients underwent surgical treatment; the overall resection rate was 59.2% (71/120), and the R0 resection rate was 40.8% (49/120). Compared with non-R0 treatment, the patients receiving an R0 resection had smaller size tumor (P < 0.01), cystadenocarcinoma (P < 0.01), less lymph node metastasis (P < 0.01), less peri-pancreatic organ involvement (P < 0.01) and earlier stage disease (P < 0.01). The overall 1-, 3-and 5-year survival rates for pancreatic body and tail cancer patients were 12.7% (25/197), 7.6% (15/197) and 2.5% (5/197), respectively, and ductal adenocarcinoma patients had worse survival rates [15.0% (9/60), 6.7% (4/60) and 1.7% (1/60), respectively] than cystadenocarcinoma patients [53.8% (21/39), 28.2% (11/39) and 10.3% (4/39)] (P < 0.01). Moreover, the 1-, 3-and 5-year overall survival rates in patients with R0 resection were 55.3% (26/47), 31.9% (15/47) and 10.6% (5/47), respectively, significantly better than those in patients with palliative resection [9.5% (2/21), 0 and 0] and in patients with bypass or laparotomy [1.2% (1/81), 0 and 0] (P < 0.01). CONCLUSION:Early diagnosis is crucial for increasing the radical resection rate, and radical resection plays an important role in improving survival for pancreatic body and tail cancer patients.

show abstract

Analysis of Long-term Survivors After Surgical Resection for Pancreatic Cancer

Abstract: Active surgical resection should be attempted even in patients with poor prognostic factors. As there were various types of pathology among the long-term survivors, typical ductal adenocarcinoma of the pancreas might have a poorer survival rate.

Cited by 150 publications

References 23 publications

Pathological tumor size is an independent prognostic factor in pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy with S-1

Pathological tumor size is an independent prognostic factor in pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy with S-1

Stromal galectin-1 expression is associated with long-term survival in resectable pancreatic ductal adenocarcinoma

Radical resection and outcome for malignant tumors of thepancreatic body and tail

Contact Info

Product

Resources

About